Fig. 3. (a) Cellular uptake of [18F] in PC3 prostate cancer cells in the presence of [18F]FAC-FDG-1 upon treatment with 0, 200, 500, or 1000 μM FA or 1000 μM FA plus cytochalasin B (10 μg mL–1). (b) Time-dependent cellular uptake of [18F] in PC3 prostate cancer cells in the presence of [18F]FAC-FDG-1 upon treatment with 1000 μM FA.
